Closing Bell Closing Bell: Is AI Artificially Inflated? 10/6/25
Oct 6, 2025
Michelle Ross, Chief Investment Officer at StemPoint Capital and a savvy biotech fund manager, dives into the world of small- and mid-cap biotech opportunities. She discusses the catalysts behind biotech's recent rally, like new policy signals and lucrative M&A activities. Ross also breaks down the impressive data results from Unicure's gene therapy and highlights which biotech stocks, such as Abivax and ScholarRock, show promising upside. Her insights reveal why these companies could be the next big winners in the biotech space.
AI Snips
Chapters
Transcript
Episode notes
Bubble In Bubble Fears
- Valuations are high but strong earnings and resilient fundamentals support the market.
- Ed Yardeni says the market discounts a resilient economy that may keep P/E levels elevated.
AI Is Useful But Not Perfect
- AI is powerful for routine tasks and productivity but remains probabilistic and fallible.
- Yardeni uses AI as a research assistant but still verifies outputs because it can make mistakes.
AI Infrastructure Arms Race
- OpenAI's AMD deal signals broader multi-vendor chip strategies and validates AI infrastructure demand.
- Dan Ives sees this as early innings with hyperscalers and enterprises increasing AI spend significantly.